IL-15 Cytokine: Structure and Function, Immunoregulatory Mechanisms, and Clinical Translation Prospects

I. Overview: The Central Hub Role of IL-15 in Adaptive and Innate Immunity

Interleukin-15 (IL-15) is a member of the γc (common γ-chain) cytokine family, sharing the IL-2Rγ chain (CD132) with IL-2, IL-4, IL-7, and others. IL-15 exerts pleiotropic functions in the immune system, serving as a key regulatory factor bridging innate and adaptive immunity. Its primary physiological roles include promoting the development, survival, and functional activation of natural killer (NK) cells, maintaining the long-term survival and homeostasis of memory CD8⁺ T cells, and supporting the survival of intraepithelial lymphocytes (IELs) and NKT cells. Unlike IL-2, IL-15 is mainly produced by monocytes/macrophages, dendritic cells, and stromal cells. Its expression and presentation are tightly regulated at multiple levels, including transcription, translation, and "trans-presentation," making it indispensable in immune homeostasis, anti-infective immunity, and tumor immune surveillance.

II. Molecular Characteristics and Expression Regulation Mechanisms

Gene and Protein Structure:

The human IL15 gene is located on chromosome 4q31, but its protein expression is tightly regulated. Mature IL-15 is a 14-15 kDa glycoprotein that functions as a non-covalently bound homodimer. Its three-dimensional structure belongs to the typical short-chain four-α-helix bundle cytokine family.

Complex Expression and Presentation Regulation:

IL-15 exhibits unique expression regulation:

Transcriptional and Post-Translational Regulation: The 5' and 3' untranslated regions (UTRs) of IL-15 mRNA contain inhibitory elements, resulting in low basal translation efficiency. Specific stimuli (e.g., TLR agonists) can relieve this inhibition and promote protein synthesis.

Unique "Trans-Presentation" Mechanism: This is the core feature of IL-15 functionality. IL-15 binds to the high-affinity IL-15 receptor α chain (IL-15Rα) within producer cells, forming an IL-15/IL-15Rα complex. This complex is transported to the cell surface and "trans-presented" by producer cells (e.g., dendritic cells) to neighboring target cells (e.g., NK cells or T cells) expressing the IL-2/15Rβγc receptor. This intercellular delivery ensures precise and localized signaling, avoiding systemic overactivation.

Receptor System:

The high-affinity IL-15 receptor consists of a trimeric complex of IL-15Rα (private chain), IL-2/15Rβ (CD122, shared with IL-2), and γc chain (CD132). IL-15Rα plays a critical role in trans-presentation and can be shed from the membrane to form a soluble form, regulating IL-15 bioavailability.

III. Signaling Pathways and Major Biological Functions

IL-15 activates downstream JAK-STAT, MAPK, and PI3K-Akt pathways by binding to receptor complexes on target cells, but its functional spectrum differs significantly from that of IL-2.

Major Target Cells and Functions:

Natural Killer (NK) Cells: IL-15 is essential for NK cell development, maturation, survival, cytotoxic function (e.g., perforin and granzyme expression), and cytokine (e.g., IFN-γ) production.

CD8⁺ Memory T Cells: Unlike IL-2, which primarily promotes activation-induced cell death (AICD), IL-15 is a key homeostatic factor for maintaining the long-term survival, homeostatic proliferation, and functional memory of memory CD8⁺ T cells.

Innate-like Lymphocytes: Critical for the development and maintenance of intraepithelial lymphocytes (IELs), NKT cells, and certain subsets of innate lymphoid cells (ILCs).

Effects on CD4⁺ T Cells and B Cells: Under specific conditions, it can enhance CD4⁺ T cell (particularly Th1) responses and support B cell reactions in germinal centers.

Signaling Characteristics:

Through JAK1/JAK3 phosphorylation of STAT5 (mainly STAT5A/B), it induces the expression of anti-apoptotic proteins (e.g., Bcl-2, Mcl-1), promoting cell survival and metabolic adaptation.

IV. Pathophysiological Roles and Clinical Relevance

Immunodeficiency Diseases:

Patients with IL-15 or IL-15Rα deficiency exhibit severe NK cell and CD8⁺ T cell deficiencies, making them susceptible to viral infections, underscoring its necessity in host defense.

Autoimmune and Inflammatory Diseases:

IL-15 is overexpressed in tissue inflammation associated with rheumatoid arthritis, psoriasis, celiac disease, and inflammatory bowel disease, exacerbating pathological damage by activating innate and adaptive immune cells.

Tumor Immunology:

Pro-Tumor Effects: In certain lymphomas (e.g., T-cell large granular lymphocytic leukemia), IL-15 may promote tumor cell survival via autocrine/paracrine loops.

Anti-Tumor Potential: More importantly, IL-15 is an ideal candidate for enhancing anti-tumor immunity. It significantly expands and activates NK cells and antigen-specific CD8⁺ T cells without inducing regulatory T cell (Treg) expansion or activation-induced cell death (AICD), making it highly attractive for combination strategies with adoptive cell therapies (e.g., CAR-T, CAR-NK) and cancer vaccines.

V. Therapeutic Targeting and Drug Development Strategies

Due to its potent immunostimulatory properties, IL-15 has become a focal point in tumor immunotherapy research.

Recombinant IL-15 Protein:

Early clinical trials using intravenous recombinant human IL-15 confirmed its ability to significantly expand peripheral NK cells and CD8⁺ memory T cells. However, systemic administration may cause severe toxicities such as cytokine release syndrome (CRS).

IL-15 Superagonist Complexes:

This is the current mainstream research direction. Fusing IL-15 with the sushi domain of high-affinity IL-15Rα (e.g., IL-15N72D/IL-15Rα-Fc, ALT-803) creates "superagonists." These complexes exhibit higher stability, significantly prolonged half-lives, and more efficient binding to IL-2/15Rβγc on target cells, resulting in stronger and more durable immune stimulation while partially improving pharmacokinetics and safety.

Targeted Delivery and Local Application:

Engineering IL-15 for localized expression in the tumor microenvironment (e.g., via oncolytic viruses or genetically engineered cells) or fusing it with tumor-targeting antibodies (immunocytokines) aims to enhance efficacy while reducing systemic toxicity.

Combination Therapies:

Combining IL-15 with immune checkpoint inhibitors (e.g., anti-PD-1), cancer vaccines, or adoptive cell therapies shows great potential for synergistic effects.

VI. Research Challenges and Future Perspectives

The primary challenge lies in precisely modulating IL-15 activity to achieve an optimal balance between efficacy and toxicity. Future directions include: developing more targeted novel IL-15 variants or agonists; elucidating the specific mechanisms of IL-15 in different tumor microenvironments and disease contexts; identifying biomarkers predictive of therapeutic response; and exploring its potential in anti-chronic infection and vaccine adjuvant applications.

Summary

IL-15 is a uniquely functional and finely regulated core immune cytokine. It serves not only as a cornerstone for maintaining NK cell and memory T cell homeostasis but also as a bridge linking innate and adaptive immune responses. With deepening understanding of its biological properties and the development of novel engineered drugs, IL-15 is rapidly transitioning from a hotspot in basic immunology research to a highly promising tumor immunotherapy agent, offering new effective strategies for cancer and infectious disease treatment.